pDGXHP1.0-HEV戊型肝炎病毒汉逊酵母重组表达质粒载体 BioVector NTCC质粒载体菌种细胞基因保藏中心

pDGXHP1.0-HEV戊型肝炎病毒汉逊酵母重组表达质粒载体

To develop a new recombinant hepatitis E vaccine, we used Hansenula polymorpha expression system to
express recombinant hepatitis E virus-like particles (HEV VLPs), to construct a recombinant engineered strain HP/HEV2.3.
The fermentation conditions and purification process were studied next. The first working seed lots were fermented in
liquid culture, and the fermentation products were collected, then crushed, clarified, purified by ultrafiltration, silica gel
adsorbed and desorbed, concentrated by ultrafiltration, purified by liquid chromatography and sterilized by filtration. The
purity reached 99% with a yield of 33%. Electron microscopy analysis revealed that both the purified recombinant HEV
VLPs from HP/HEV2.3 and natural hepatitis E virus particles appear identical of being 32 nm. The resulting DNA sequence
obtained from VLPs is identical to the published HEV sequence. The SDS-PAGE analysis has revealed that the protein
molecular weight of the HEV VLPs is 56 kDa, and the expression product HEV VLPs were accumulated up to 26% of total
cellular protein. The expression level is 1.0 g/L. Western blotting, enzyme-linked immunosorbent assay (ELISA) results of
the protein and ED50 of the vaccine showed that the HEV VLPs have good antigenicity and immunogenicity. In summary,
the recombinant HEV VLPs from Hansenula polymorpha can be used in the manufacture of a new genetically engineered
vaccine against hepatitis E.

Supplier来源:BioVector NTCC Inc.
TEL电话:400-800-2947
Website网址: http://www.biovector.net